Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: A randomized crossover study

BMC Clinical Pharmacology

Volumn 8, Issue , 2008, Pages

  Chan, Sammy Y ^a,b   Mancini, G B John ^a,b   Ignaszewski, Andrew ^a,b   Frohlich, Jiri ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; CLOFIBRIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; PLACEBO;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CLASSIFICATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE; PROSPECTIVE STUDY;

AGED; CLOFIBRIC ACID; CROSS-OVER STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; PLACEBOS; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 57049109735     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-8-10     Document Type: Article

References (25)

1. Grundy SM Cleeman JI Merz CN Brewer HB Jr Clark LT Hunninghake DB Pasternak RC Smith SC Jr Stone NJ Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 2004, 44(3):720-732. 10.1016/ j.jacc.2004.07.001 15358046
2. McPherson R Frohlich J Fodor G Genest J Canadian Cardiovascular S Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 2006, 22(11):913-927. 16971976
3. Krauss RM Burke DJ Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 1982, 23(1):97-104. 7057116
4. Gazi IF Tsimihodimos V Tselepis AD Elisaf M Mikhailidis DP Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles Expert Opin Biol Ther 2007, 7(1):53-72. 10.1517/ 14712598.7.1.53 17150019
5. Zambon A Hokanson JE Brown BG Brunzell JD Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density Circulation 1999, 99(15):1959-1964. 10208998
6. Zambon A Brown BG Hokanson JE Motulsky AG Brunzell JD Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy J Intern Med 2006, 259(4):401-409. 10.1111/j.1365-2796.2006.01626.x 16594908
7. Ensign W Hill N Heward CB Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics Clin Chem 2006, 52(9):1722-1727. 10.1373/clinchem.2005.059949 16740651
8. Otvos JD Jeyarajah EJ Cromwell WC Measurement issues related to lipoprotein heterogeneity Am J Cardiol 2002, 90(8A):22i-29i. 10.1016/ S0002-9149(02)02632-2 12419478
9. Robins SJ Bloomfield HE Fibric acid derivatives in cardiovascular disease prevention: Results from the large clinical trials Curr Opin Lipidol 2006, 17(4):431-439. 10.1097/01.mol.0000236370.27508.9d 16832168
10. Phillips NR Waters D Havel RJ Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events Circulation 1993, 88(6):2762-2770. 8252689
11. Krauss RM Lindgren FT Williams PT Kelsey SF Brensike J Vranizan K Detre KM Levy RI Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men Lancet 1987, 2(8550):62-66. 10.1016/S0140-6736(87)92734-6 2885572
12. Hodis HN Mack WJ Azen SP Alaupovic P Pogoda JM LaBree L Hemphill LC Kramsch DM Blankenhorn DH Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin Circulation 1994, 90(1):42-49. 8026027
13. Watts GF Mandalia S Brunt JN Slavin BM Coltart DJ Lewis B Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS) Metabolism 1993, 42(11):1461-1467. 10.1016/ 0026-0495(93)90199-X 8231842
14. Miller BD Alderman EL Haskell WL Fair JM Krauss RM Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project Circulation 1996, 94(9):2146-2153. 8901665
15. Otvos JD Collins D Freedman DS Shalaurova I Schaefer EJ McNamara JR Bloomfield HE Robins SJ Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 2006, 113(12):1556-1563. 10.1161/CIRCULATIONAHA.105.565135 16534013
16. Ikewaki K Tohyama J Nakata Y Wakikawa T Kido T Mochizuki S Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study J Atheroscler Thromb 2004, 11(5):278-285. 15557710
17. Ikewaki K Noma K Tohyama J Kido T Mochizuki S Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia-a nuclear magnetic resonance study Int J Cardiol 2005, 101(3):441-447. 10.1016/j.ijcard.2004.03.071 15907413
18. May HT Anderson JL Pearson RR Jensen JR Horne BD Lavasani F Yannicelli HD Muhlestein JB Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study) Am J Cardiol 2008, 101(4):486-489. 10.1016/j.amjcard.2007.09.095 18312763
19. Miller M Dolinar C Cromwell W Otvos JD Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia Am J Cardiol 2001, 87(2):232-234. 10.1016/S0002-9149(00)01327-8 11152850
20. Soedamah-Muthu SS Colhoun HM Thomason MJ Betteridge DJ Durrington PN Hitman GA Fuller JH Julier K Mackness MI Neil HA The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease Atherosclerosis 2003, 167(2):243-255. 10.1016/ S0021-9150(02)00428-8 12818407
21. Melenovsky V Malik J Wichterle D Simek J Pisarikova A Skrha J Poledne R Stavek P Ceska R Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia Am Heart J 2002, 144(4):E6. 12360175
22. Frost RJ Otto C Geiss HC Schwandt P Parhofer KG Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia Am J Cardiol 2001, 87(1):44-48. 10.1016/S0002-9149(00)01270-4 11137832
23. Winkler K Weltzien P Friedrich I Schmitz H Nickell HH Hauck P Hoffmann MM Baumstark MW Wieland H Marz W Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL Exp Clin Endocrinol Diabetes 2004, 112(5):241-247. 10.1055/s-2004-817970 15146369
24. El Harchaoui K Steeg van der WA Stroes ES Kuivenhoven JA Otvos JD Wareham NJ Hutten BA Kastelein JJ Khaw KT Boekholdt SM Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 2007, 49(5):547-553. 10.1016/j.jacc.2006.09.043 17276177
25. Mora S Szklo M Otvos JD Greenland P Psaty BM Goff DC Jr O'Leary DH Saad MF Tsai MY Sharrett AR LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 2006.